Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients

Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection

(2013) Ting C Zhao   Cardiovascular Diabetology

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

(2013) Katja Piotrowski et al.   Cardiovascular Diabetology

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat

(2013) Weike Bao et al.   Cardiovascular Diabetology

Banting Lecture 2012: Regulation of Adipogenesis: Toward New Therapeutics for Metabolic Disease

(2013) B. M. Spiegelman   DIABETES

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

(2013) Minsuk Kim et al.   NATURE MEDICINE

Impact of Waist Circumference and Body Mass Index on Risk of Cardiometabolic Disorder and Cardiovascular Disease in Chinese Adults: A National Diabetes and Metabolic Disorders Survey

(2013) Xuhong Hou et al.   PLoS One

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

(2012) Yuya Fujishima et al.   Cardiovascular Diabetology

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

(2012) Chun-jun Li et al.   Cardiovascular Diabetology

Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes

(2012) Marica Bordicchia et al.   JOURNAL OF CLINICAL INVESTIGATION

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

(2011) Kana Inoue et al.   Cardiovascular Diabetology

Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance

(2011) Joan Vendrell et al.   ENDOCRINOLOGY

Cardiac Natriuretic Peptides, Obesity, and Insulin Resistance: Evidence from Two Community-Based Studies

(2011) Abigail May Khan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats

(2011) Matthew R. Hayes et al.   Obesity

Relation of B-Type Natriuretic Peptide Levels to Body Mass Index After Comprehensive Lifestyle Changes

(2010) Nita Chainani-Wu et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effect of Weight Loss After Weight Loss Surgery on Plasma N-Terminal Pro-B-Type Natriuretic Peptide Levels

(2010) Annabel Chen-Tournoux et al.   AMERICAN JOURNAL OF CARDIOLOGY

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Functional Brown Adipose Tissue in Healthy Adults

(2009) Kirsi A. Virtanen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and Importance of Brown Adipose Tissue in Adult Humans

(2009) Aaron M. Cypess et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans

(2008) A. L. Birkenfeld et al.   DIABETES

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET